Patient Medication Guide
Send prescription data safely and securely.
Step 1
Medication library
Singulair (montelukast sodium) 10 mg tablet, film coatedPlain-language guide · Citations availableLabel effective 2025-04-30Select medication →Toprol Xl (metoprolol succinate) 50 mg tablet, extended releaseFDA label text · Not yet rewrittenLabel effective 2026-03-03Select medication →Ozempic (semaglutide) 1.34 mg/1 mL injection, solutionFDA label text · Not yet rewrittenLabel effective 2026-06-01Selected ✓Source-backed education. No clinical review has been performed.
Step 2
Patient guide preview
Ozempic (semaglutide) 1.34 mg/1 mL injection, solution
Will be updated when more information is available.
What the patient will see
FDA Boxed Warning: important safety informationBoxed warning
WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ). • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors ( 4 , 5.1 ).
1 citation from the FDA label.
What is this medication?
Will be updated when more information is available.
0 citations from the FDA label.
What is it approved to treat?
Will be updated when more information is available.
0 citations from the FDA label.
Important limitations: what it does not doSafety
Will be updated when more information is available.
0 citations from the FDA label.
Common side effects
Will be updated when more information is available.
0 citations from the FDA label.
Serious risks to understandSafety
Will be updated when more information is available.
0 citations from the FDA label.
Who should not take it, and drug interactions
Will be updated when more information is available.
0 citations from the FDA label.
Pregnancy, children, and older adults
Will be updated when more information is available.
0 citations from the FDA label.
How it is taken (as described in the label)
Will be updated when more information is available.
0 citations from the FDA label.
Reporting a side effect
Will be updated when more information is available.
0 citations from the FDA label.